Kawasaki disease: Current aspects on aetiopathogenesis and therapeutic management

被引：29

作者：

Alexoudi, Iliana ^{[1
]}

Kanakis, Meletios

Kapsimali, Violetta ^{[1
]}

Vaiopoulos, George ^{[1
]}

机构：

[1] Univ Athens, Dept Microbiol, Athens 11527, Greece

来源：

AUTOIMMUNITY REVIEWS | 2011年 / 10卷 / 09期

关键词：

Kawasaki disease; Vasculitis; Aetiopathogenesis; Treatment; INTRAVENOUS IMMUNE GLOBULIN; AMERICAN-HEART-ASSOCIATION; LONG-TERM MANAGEMENT; CARDIOVASCULAR-DISEASE; HEALTH-PROFESSIONALS; RHEUMATIC-FEVER; IMMUNOGLOBULIN; INFLIXIMAB; MATRIX-METALLOPROTEINASE-9; METHYLPREDNISOLONE;

D O I：

10.1016/j.autrev.2011.04.005

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Kawasaki disease (KD) is a vasculitis that affects mainly children of 6 months to 4 years old. It is important to be early recognised so as to limit the inflammatory cascade that may lead to aneurysmatic dilatations of coronary arteries. The causative agent of KD has not been still indentified and the aetiopathogenetic theories are based on epidemiologic, laboratory and histological data. The management of the disease is divided according to the clinical stage and patients' follow up should be continued for years after the disease onset. The exact period is determined by the risk level of the KD. (C) 2011 Elsevier B.V. All rights reserved.

引用

收藏

页码：544 / 547

页数：4

相关论文

共 26 条

[1] CD8 T lymphocytes and macrophages infiltrate coronary artery aneurysms in acute Kawasaki disease [J].

Brown, TJ ;

Crawford, SE ;

Cornwall, ML ;

Garcia, F ;

Shulman, ST ;

Rowley, AH .

JOURNAL OF INFECTIOUS DISEASES, 2001, 184 (07) :940-943

[2] Kawasaki disease: What is the epidemiology telling us about the etiology? [J].

Burgner, D ;

Harnden, A .

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2005, 9 (04) :185-194

[3] Infliximab Treatment of Intravenous Immunoglobulin-Resistant Kawasaki Disease [J].

Burns, Jane C. ;

Best, Brookie M. ;

Mejias, Asuncion ;

Mahony, Lynn ;

Fixler, David E. ;

Jafri, Hasan S. ;

Melish, Marian E. ;

Jackson, Mary Anne ;

Asmar, Basim I. ;

Lang, David J. ;

Connor, James D. ;

Capparelli, Edmund V. ;

Keen, Monica L. ;

Mamun, Khalid ;

Keenan, Gregory F. ;

Ramilo, Octavio .

JOURNAL OF PEDIATRICS, 2008, 153 (06) :833-838

[4] Prospective Open-Label Trial of Etanercept as Adjunctive Therapy for Kawasaki Disease [J].

Choueiter, Nadine F. ;

Olson, Aaron K. ;

Shen, Danny D. ;

Portman, Michael A. .

JOURNAL OF PEDIATRICS, 2010, 157 (06) :960-U148

[5] Kawasaki disease: Aetiopathogenesis and therapeutic utility of intravenous immunoglobulin [J].

Galeotti, Caroline ;

Bayry, Jagedeesh ;

Kone-Paut, Isabelle ;

Kaveri, Srinivas V. .

AUTOIMMUNITY REVIEWS, 2010, 9 (06) :441-448

[6] Editor's Focus [J].

Pediatric Research, 2009, 65 (6) :5-5

[7] Risk Stratification in the Decision to Include Prednisolone With Intravenous Immunoglobulin in Primary Therapy of Kawasaki Disease [J].

Kobayashi, Tohru ;

Inoue, Yoshinari ;

Otani, Tetsuya ;

Morikawa, Akihiro ;

Kobayashi, Tomio ;

Takeuchi, Kazuo ;

Saji, Tsutomu ;

Sonobe, Tomoyoshi ;

Ogawa, Shunichi ;

Miura, Masaru ;

Arakawa, Hirokazu .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2009, 28 (06) :498-502

[8] Serum albumin level predicts initial intravenous immunoglobulin treatment failure in Kawasaki disease [J].

Kuo, Ho-Chang ;

Liang, Chi-Di ;

Wang, Chih-Lu ;

Yu, Hong-Ren ;

Hwang, Kao-Pin ;

Yang, Kuender D. .

ACTA PAEDIATRICA, 2010, 99 (10) :1578-1583

[9] Inhibition of matrix metalloproteinase-9 activity improves coronary outcome in an animal model of Kawasaki disease [J].

Lau, A. C. ;

Duong, T. T. ;

Ito, S. ;

Wilson, G. J. ;

Yeung, R. S. M. .

CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2009, 157 (02) :300-309

[10] Kawasaki syndrome: Immunomodulatory benefit and potential toxin neutralization by intravenous immune globulin [J].

Leung, DYM .

CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1996, 104 :49-54